sur Xlife Sciences AG (isin : CH0461929603)
Xlife Sciences AG Announces Strategic Merger Between palleos healthcare GmbH and OCT Clinical GmbH
Zurich, 27th of May 2024: Xlife Sciences AG announced the merger of its portfolio company, palleos healthcare GmbH, with OCT Clinical GmbH. This merger aims to form a leading entity in clinical research.
palleos healthcare, a Germany-based contract research organization (CRO) focused on oncology, and OCT Clinical, a full-service CRO, have completed their merger following the signing of the contract on May 24, 2024.
Combining the strengths of both companies, the merger positions them to offer comprehensive services globally. With palleos healthcare operating primarily in Western and Central Europe and OCT Clinical in Eastern Europe, the new entity will now serve over 300 million people and will be branded as palleos healthcare.
Dr. Philip Räth, Managing Director of palleos healthcare, noted the synergistic benefits, while Dmitry Sharov, CEO of OCT Clinical, highlighted the enhanced service capabilities. Oliver R. Baumann, CEO of Xlife Sciences, expressed enthusiasm about the merger's potential to offer better CRO solutions for global markets.
R. E.Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés. Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Xlife Sciences AG